Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coherus OncologyFRA:8C5 +4.17%59 Equity-to-Asset is 0.32 as of Jun. 2026, which is 100% above its 10-year median of 0.16. GuruFocus rates FRA:8C5 with a GF Score™ of 59/100 and a GF Value™ of €0.89. The stock has 7 warning signs investors should review. Among 1,410 Biotechnology companies, Coherus Oncology ranks worse than 78.51% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Coherus Oncology's Total Stockholders Equity for the quarter that ended in Jun. 2026 was €53.21 Mil. Coherus Oncology's Total Assets for the quarter that ended in Jun. 2026 was €167.22 Mil.
Therefore, Coherus Oncology's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.32.
The historical rank and industry rank for Coherus Oncology's Equity-to-Asset or its related term are showing as below:
FRA:8C5'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.49 Med: 0.16 Max: 0.34
Current: 0.32
During the past 13 years, the highest Equity to Asset Ratio of Coherus Oncology was 0.34. The lowest was -0.49. And the median was 0.16.
FRA:8C5's Equity-to-Asset is ranked worse than 78.51% of 1410
companies
in the Biotechnology industry
Industry Median: 0.69
vs FRA:8C5: 0.32
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Coherus Oncology Equity-to-Asset Related Terms
Coherus Oncology Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Coherus Oncology's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8C5 vs VYGR, KROS, DTIL: Equity-to-Asset Comparison
For the Biotechnology subindustry, Coherus Oncology's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Coherus Oncology's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coherus Oncology (FRA:8C5) has a Equity-to-Asset of 0.32 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Coherus Oncology and its competitors. This is 100% above median its historical median of 0.16. According to the industry distribution chart, Coherus Oncology ranks #1107 out of 1410 companies in the Biotechnology industry, placing it in the top 78.5%.
Is Coherus Oncology's Equity-to-Asset too high?
Coherus Oncology's current Equity-to-Asset of 0.32 is 100% above median its 10-year median of 0.16. The Biotechnology industry median Equity-to-Asset is 0.69. Coherus Oncology's value of 0.32 is 53.6% below this industry median. Based on the distribution chart, Coherus Oncology ranks #1107 out of 1410 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Coherus Oncology has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's Equity-to-Asset compare to VYGR and KROS?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #1107 out of 1410 companies for Equity-to-Asset. This places Coherus Oncology in the lower half of its industry. The industry median Equity-to-Asset is 0.69. Coherus Oncology's value of 0.32 is 53.6% below this benchmark. While the company's 10-year median is 0.16 vs. the industry median of 0.69, Coherus Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coherus Oncology's current Equity-to-Asset of 0.32 is 53.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Coherus Oncology and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coherus Oncology's current Equity-to-Asset is 0.32, which is 100% above median its own 10-year median of 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Coherus Oncology (FRA:8C5) has a current Equity-to-Asset of 0.32. The stock's GF Value™ is €0.89, compared to a current price of €1.17 — trading 31.1% above its estimated fair value. The current Equity-to-Asset is 0.32, which is 100% above median its 10-year median of 0.16 and 53.6% below the Biotechnology industry median of 0.69. Coherus Oncology's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current Equity-to-Asset is 0.32 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (FRA:8C5) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of €1.17 is trading 31.1% above its estimated GF Value™ of €0.89.
Key valuation signals for FRA:8C5:
Equity-to-Asset: 0.32 (100% above median its 10-year median of 0.16)
GF Value™: €0.89 vs. price of €1.17 (31.1% above fair value)
Industry Position: 53.6% below the Biotechnology median (#1107 of 1410)
No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
59GF Score
Get the complete analysis for FRA:8C5
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8C5 has been successfully added to your 
